# Treatment and Management of Diabetes Mellitus

## Management Principles

### Patient-Centered Approach
- **Individualized targets**: Based on age, comorbidities, life expectancy
- **Shared decision-making**: Patient preferences and values
- **Team-based care**: Multidisciplinary approach
- **Cultural sensitivity**: Address social and cultural factors

### Glycemic Targets (ADA 2024)
- **HbA1c**: <7.0% for most patients (<6.5% for younger, healthy patients)
- **Preprandial glucose**: 80-130 mg/dL
- **Postprandial glucose**: <180 mg/dL (2 hours after meal)
- **Time in range**: >70% (CGM targets)

### Algorithm-Based Treatment
- **Stepwise intensification**: Start simple, progress systematically
- **Monotherapy to combination**: Based on failure to achieve targets
- **Lifestyle foundation**: Always include non-pharmacological measures
- **Regular reassessment**: Quarterly review of targets and progress

## Non-Pharmacological Management

### Diabetes Self-Management Education (DSME)
- **Core curriculum**: Disease process, treatment options, problem-solving
- **Behavioral strategies**: Goal setting, motivation, coping skills
- **Ongoing support**: Follow-up reinforcement
- **Cultural adaptation**: Tailored to local context

### Medical Nutrition Therapy (MNT)
- **Calorie control**: 500 kcal deficit for weight loss
- **Carbohydrate counting**: 45-60% of total calories
- **Glycemic index/load**: Low GI foods preferred
- **Protein**: 15-20% of calories
- **Fat**: <30% calories, <10% saturated

#### Indian Dietary Guidelines
- **Regional foods**: Rice-based South, wheat-based North
- **Cultural foods**: Incorporate traditional meals
- **Portion control**: Use local measuring units
- **Festival foods**: Healthy modifications

### Physical Activity
- **Aerobic exercise**: 150 minutes/week moderate intensity
- **Resistance training**: 2-3 sessions/week
- **Flexibility**: Daily stretching
- **NEAT**: Non-exercise activity thermogenesis
- **Yoga/meditation**: Stress reduction benefits

#### Indian Context
- **Walking/cycling**: Promote instead of motorized transport
- **Workplace activity**: Standing desks, walking meetings
- **Family involvement**: Group activities
- **Seasonal adaptation**: Indoor activities during monsoon

### Weight Management
- **BMI targets**: 18.5-22.9 kg/m² (South Asian cutoffs)
- **Weight loss**: 5-10% for metabolic improvement
- **Waist reduction**: Primary target for central obesity
- **Sustainable methods**: Behavior change vs. crash diets

## Pharmacological Management

### Type 2 Diabetes Treatment Algorithm

#### First-Line Therapy
- **Metformin**: 500-1000 mg twice daily
- **Mechanisms**: ↓ Hepatic glucose output, ↑ peripheral glucose uptake
- **Side effects**: GI upset, vitamin B12 deficiency
- **Contraindications**: Renal impairment, lactic acidosis risk

#### Second-Line Additions
- **DPP-4 inhibitors** (Gliptins): Sitagliptin, Vildagliptin, Teneligliptin
- **SGLT2 inhibitors** (Flozins): Empagliflozin, Dapagliflozin, Canagliflozin
- **GLP-1 receptor agonists**: Dulaglutide, Semaglutide (weekly)
- **TZDs** (Thiazolidinediones): Pioglitazone (limited use)

#### Third-Line Therapy
- **Basal insulin**: Long-acting (Glargine, Degludec, Detemir)
- **Premixed insulin**: Biphasic insulin aspart/lispro
- **Triple oral therapy**: Limited utility

### Type 1 Diabetes Management
- **Basal-bolus regime**: Long-acting + rapid-acting insulins
- **Basal insulin**: Glargine U300 or Degludec (once daily)
- **Bolus insulin**: Aspart, Lispro, Glulisine (pre-meal)
- **Algorithm**: Insulin-to-carbohydrate ratio, correction factor
- **Advanced systems**: Insulin pumps, CGM, hybrid closed-loop

### Insulin Therapy Principles
- **Dose titration**: Adjust based on SMBG patterns
- **Basal-prandial balance**: 40-60% basal, 40-60% prandial
- **Correction doses**: 1:50 rule (1 unit reduces glucose by 50 mg/dL)
- **Injection technique**: Proper rotation, timing
- **Storage**: Refrigerate until opened, room temp after

### Oral Hypoglycemics

#### Sulfonylureas
- **Mechanism**: Insulin secretion stimulation
- **Examples**: Glimepiride, Glipizide, Gliclazide
- **Dosing**: Once/twice daily, with meals
- **Hypoglycemia risk**: Higher with longer-acting agents
- **Weight effect**: Mild weight gain

#### Meglitinides
- **Repaglinide, Nateglinide**: Short-acting, meal-related
- **Advantages**: Lower hypoglycemia risk
- **Use**: Add-on to metformin
- **Dosing**: Before each meal

#### Biguanides
- **Metformin**: First-line in all guidelines
- **GI side effects**: Start low, titrate slowly
- **Renal dosing**: CrCl 30-45 mL/min = 1000 mg/d

#### Thiazolidinediones
- **Pioglitazone**: PPAR-gamma agonists
- **Effects**: Insulin sensitization, anti-inflammatory
- **Side effects**: Weight gain, edema, fracture risk
- **Cardioprotection**: Limited evidence

#### DPP-4 Inhibitors
- **Gliptins**: Glucose-dependent insulin secretion
- **Safety profile**: Weight neutral, low hypoglycemia
- **Renal adjustment**: Most do not require
- **CV safety**: Neutral (some CV benefit)

#### SGLT2 Inhibitors
- **Flozins**: Renal glucose excretion
- **CV/kidney benefits**: Empagliflozin, Canagliflozin proven
- **Side effects**: Genital infections, euglycemic DKA
- **Monitoring**: Volume status, urinary glucose

#### GLP-1 Receptor Agonists
- **Incretin mimetics**: Glucose-dependent insulin + glucagon
- **Weight loss effect**: 3-5 kg reduction
- **CV benefits**: Some agents proven
- **Administration**: Subcutaneous injection

### Combination Therapy
- **Rational combinations**: Complementary mechanisms
- **Fixed-dose combinations**: Improved adherence
- **Steady progression**: Metformin + single daily dose to complex regimens
- **Cost considerations**: Generic availability in India

## Management in Special Populations

### Elderly Patients (≥65 years)
- **Liberalized targets**: HbA1c 7.5-8.5%
- **Hypoglycemia awareness**: Use short-acting agents
- **Polypharmacy**: Minimize drug interactions
- **Functional status**: Consider frailty, comorbidities
- **Nursing home**: Simplified regimens

### Pediatric Diabetes
- **T1DM standard care**: Basal-bolus regimen
- **School support**: Individualized education plans
- **Growth monitoring**: Height velocity assessment
- **Psychosocial support**: Peer groups, counseling
- **ADA goals**: HbA1c <7.5% (relaxed vs adults)

### Pregnancy and Diabetes
- **Pre-conception**: Optimize control, folate supplementation
- **GDM treatment**: Diet first, insulin/oral agents if needed
- **T1DM pregnancy**: Tight control, frequent monitoring
- **Target HbA1c**: <6.5% preconception and pregnancy
- **Delivery planning**: Neonatal hypoglycemia prevention

### Chronic Kidney Disease
- **Drug adjustment**: Based on eGFR
- **Hypoglycemia risk**: Increased in CKD
- **Metformin**: Stop at eGFR <30 mL/min
- **Insulin**: Dose reduction required
- **SGLT2 inhibitors**: CV/renal benefits, careful monitoring

### Coronary Artery Disease
- **Cardioprotective agents**: SGLT2i, GLP-1 RA preferred
- **Metformin**: Preferred first-line
- **Avoid sulfonylureas**: Higher hypoglycemia risk
- **Beta-blocker interaction**: Caution with oral agents

### Liver Disease
- **Metformin**: Safe in compensated cirrhosis
- **Sulfonylureas**: Hypoglycemia risk
- **Insulin**: Preferred in decompensated liver disease
- **GLP-1 RA**: Limited data, caution advised

## Insulin Therapy Initiation and Adjustment

### Starting Insulin in T2DM
- **Basal insulin**: Add to failing oral therapy
- **Start dose**: 0.2 units/kg or 10 units as starting dose
- **Titration**: Increase by 2-4 units every 3 days based on FBS
- **Target**: FBS 80-130 mg/dL

### Switching to Insulin
- **T2DM**: Oral agents continued + insulin
- **T1DM**: All oral agents discontinued
- **Overnight hospitalization**: For complex cases
- **Patient education**: Essential before starting

### Insulin Analogues
- **Rapid-acting**: Aspart, Lispro, Glulisine (onset 10-15 min)
- **Long-acting**: Glargine, Detemir, Degludec (24-42 hour duration)
- **Premixed**: 30/70, 50/50 (regular/NPH or analogues)
- **Ultra-long**: Degludec (up to 7 days if missed)

### Insulin Delivery Devices
- **Syringes**: Most common in India due to cost
- **Pens**: Prefilled, easier for elderly
- **Pumps**: Continuous subcutaneous insulin infusion
- **Jet injectors**: Needle-free option

## Monitoring and Adjustment

### Self-Monitoring of Blood Glucose (SMBG)
- **Frequency**: 2-3 times daily on OHA, more on insulin
- **Patterns**: Pre/postprandial, bedtime
- **Decision-making**: Dose adjustment based on patterns
- **CGM**: Continuous monitoring if available

### Glycated Hemoglobin (HbA1c)
- **Frequency**: Every 3 months
- **Target attainment**: Individualized
- **Discordance**: When SMBG doesn't match HbA1c
- **Limitations**: Anemia, hemoglobinopathies

### Continuous Glucose Monitoring (CGM)
- **Real-time CGM**: Dexcom, Medtronic
- **Flash glucose monitoring**: Abbott FreeStyle Libre
- **Indications**: Unexplained hypoglycemia, pregnancy, insulin pump
- **Interpretation**: Time in range, glycemic variability

### Treatment Adjustment Algorithm
- **Review SMBG patterns**: Adjust specific doses
- **Hypoglycemia episodes**: Reduce offending dose
- **Weight changes**: Impact insulin requirements
- **Lifestyle changes**: Review diet, exercise compliance
- **Comorbidities**: Impact treatment choices

## Acute Complications Management

### Hypoglycemia Emergency
- **15-15 rule**: 15g glucose, recheck in 15 minutes
- **Severe cases**: Glucagon 1mg IM/SQ or IV dextrose
- **Prevention**: Regular meals, hypoglycemia awareness training
- **Glucagon kit**: Prescribed for patients at risk

### DKA Management
- **Fluid resuscitation**: Normal saline 1L/hour
- **Insulin infusion**: 0.14 units/kg/hour
- **Electrolyte correction**: Potassium, phosphate
- **Monitoring**: Hourly glucose, q2-4h electrolytes
- **Transition**: To subcutaneous insulin when stable

### HHS Management
- **Aggressive fluids**: Half normal saline initially
- **Insulin**: Gradual decrease in glucose
- **Underlying cause**: Infection, noncompliance
- **Monitoring**: Neurological status, fluid balance

## Multidisciplinary Team Approach

### Role of Different Specialists
- **Endocrinologist**: Complex cases, insulin initiation
- **Diabetologist**: Primary care with diabetes focus
- **Diabetes educator**: Patient education
- **Dietitian**: Nutrition planning
- **Podiatrist**: Foot care
- **Ophthalmologist**: Retinal screening

### Technology Integration
- **Mobile apps**: Self-management support
- **Digital therapeutics**: FDA-approved programs
- **Telemedicine**: Remote monitoring
- **AI-assisted care**: Predictive analytics

## Economic Considerations

### Cost-Effective Treatment
- **Generic drugs**: Metformin, sulfonylureas first-line
- **Fixed-dose combinations**: Reduce pill burden
- **Stepped care**: Start cheap, add expensive as needed
- **Government programs**: Jan Aushadhi scheme in India

### Access and Equity
- **Universal coverage**: PMJAY in India
- **Outpatient care**: NCD clinics in PHCs
- **Supply chain**: Insulin availability
- **Education programs**: Community-based screening

## Learning Objectives
- Implement patient-centered treatment approaches
- Apply pharmacological algorithms for diabetes management
- Integrate lifestyle modifications into treatment plans
- Manage special populations with diabetes
- Monitor treatment effectiveness and make adjustments
- Recognize and manage acute complications
- Coordinate multidisciplinary diabetes care
